Literature DB >> 6142478

Mechanistic studies on the high pressure neurological syndrome.

F Bowser-Riley.   

Abstract

The high pressure neurological syndrome (h.p.n.s.) constitutes a major barrier to deep sea exploration by man. Although the signs and symptoms of h.p.n.s. are well documented in both man and experimental animals, the underlying mechanisms remain to be elucidated. Physiological and pharmacological evidence will be presented that confirms that the principal sites of action of pressure are within the central nervous system (c.n.s.). Results from physiological studies not only indicate that there are separate sites of action of pressure within the c.n.s., which mediate the different components of h.p.n.s., but also the response to pressure may be controlled by descending inhibitory pathways. Pharmacological studies support this view and suggest that h.p.n.s. involves a failure of central inhibition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6142478     DOI: 10.1098/rstb.1984.0006

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  4 in total

1.  An evaluation of the structure-activity relationships of a series of analogues of mephenesin and strychnine on the response to pressure in mice.

Authors:  F Bowser-Riley; S Daniels; W A Hill; E B Smith
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

2.  Alterations in brain monoamine neurotransmitter release at high pressure.

Authors:  S C Gilman; J S Colton; A J Dutka
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

3.  Systemically administered glycine protects against strychnine convulsions, but not the behavioural effects of high pressure, in mice.

Authors:  M J Halsey; H J Little; B Wardley-Smith
Journal:  J Physiol       Date:  1989-01       Impact factor: 5.182

4.  Investigations into the origin of the high pressure neurological syndrome: the interaction between pressure, strychnine and 1,2-propandiols in the mouse.

Authors:  F Bowser-Riley; S Daniels; E B Smith
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.